0000874015-23-000130.txt : 20230419 0000874015-23-000130.hdr.sgml : 20230419 20230419201834 ACCESSION NUMBER: 0000874015-23-000130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230417 FILED AS OF DATE: 20230419 DATE AS OF CHANGE: 20230419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baroldi Joseph CENTRAL INDEX KEY: 0001813775 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 23831177 MAIL ADDRESS: STREET 1: C/O AVIDITY BIOSCIENCES, INC. STREET 2: 10975 N. TORREY PINES RD., SUITE 150 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0407 4 2023-04-17 0 0000874015 IONIS PHARMACEUTICALS INC IONS 0001813775 Baroldi Joseph 2855 GAZELLE COURT CARLSBAD CA 92010 0 1 0 0 EVP, Chief Business Officer 0 Common Stock 2023-04-17 4 M 0 10838 0.0 A 14451 D Common Stock 2023-04-18 4 S 0 3880 36.5028 D 10571 D Common Stock 851 I by Spouse Restricted Stock Unit 0.0 2023-04-17 4 M 0 10838 0.0 D Common Stock 10838 47261 D Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.20 to $36.50953 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. By: Patrick R. O'Neil, attorney-in-fact For: Joseph T. Baroldi 2023-04-19